Why People Are Losing Faith in Healthcare
Summary
Scott Galloway interviews Eli Lilly CEO David Ricks, arguing that GLP-1 drugs will have a greater societal impact than AI. They discuss how these treatments address obesity, reduce healthcare costs, and curb addictions, while Ricks explains Lilly’s trillion-dollar valuation and pricing strategies. The conversation also covers the dangers of unregulated peptides, the realistic timeline for AI in drug discovery, and Ricks’ advice on career growth and fatherhood.
Topics discussed
Intro and Ad Breaks
Introduction of David Ricks and Eli Lilly's History
GLP-1s: Mechanism, Efficacy, and Obesity Impact
Secondary Benefits: Inflammation, Addiction, and Cancer
Pricing, Accessibility, and Healthcare Economics
Ad Breaks
Peptides vs. FDA-Approved Drugs and Consumer Trust
Eli Lilly's Competitive Advantages and Execution
The Role of AI in Drug Discovery
Ad Breaks
Personal Advice, Fatherhood, and Lightning Round
Listen ad-free on Castria